1-Acetylazepane-2-carboxylic acid | 1219182-45-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Acetylazepane-2-carboxylic acid
• CAS: 1219182-45-2
• 化学式: C₉H₁₅NO₃
• 分子量: 185.22
• InChiKey: XWYTXWHLVJKYBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders
  申请人：Rajagopal Desikan

  公开号：US20110257130A1

  公开（公告）日：2011-10-20

  Compounds are provided which can be useful in reducing the activity of an angiotensin-converting enzyme and thus be used to treat or prevent a renin-angiotensin aldosterone system-related disorder. These compounds include lipoic acid derivatives such as prolyl lipoic acid and pipecolinyl lipoic acid, and other compounds, and these compounds are useful in treating hypertension, stroke, or other renin-angiotensin aldosterone system-related disorders in human or animal patients. Pharmaceutical compositions prepared using these compounds and methods of treatment using these compounds are also provided.
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE TROUBLES LIÉS AU SYSTÈME RÉNINE-ANGIOTENSINE-ALDOSTÉRONE (SRAA)
  申请人：INVASC THERAPEUTICS INC

  公开号：WO2010045575A2

  公开（公告）日：2010-04-22

  Compounds are provided which can be useful in reducing the activity of an angiotensin-converting enzyme and thus be used to treat or prevent a renin-angiotensin aldosterone system-related disorder. These compounds include lipoic acid derivatives such as prolyl lipoic acid and pipecolinyl lipoic acid, and other compounds, and these compounds are useful in treating hypertension, stroke, or other renin-angiotensin aldosterone system-related disorders in human or animal patients. Pharmaceutical compositions prepared using these compounds and methods of treatment using these compounds are also provided.